Showing 1291-1300 of 3103 results for "".
- Real-World Data Support High-Efficacy vs Low-Efficacy DMTs in Relapsing-Remitting MShttps://practicalneurology.com/news/real-world-data-support-high-efficacy-vs-low-efficacy-dmts-in-relapsing-remitting-ms/2486370/
- In Relapsing MS, BTK Inhibitor Fenebrutinib Showed Reduced Relapse Rate vs Aubagiohttps://practicalneurology.com/news/in-relapsing-ms-btk-inhibitor-fenebrutinib-reduces-relapse-rate-vs-aubagio/2485955/Key Takeaways Results from the phase 3 FENhance 1 trial showed fenebrutinib reduced annualized relapse rate compared with Aubagio in people with relapsing multiple sclerosis. Combined results from FENhance 1 a
- Data Regarding Novel CD40 Ligand Inhibitor as Potential Treatment for Individuals with Relapsing MS Presented at AAN 2025https://practicalneurology.com/news/data-regarding-novel-cd40-ligand-inhibitor-as-potential-treatment-for-individuals-with-relapsing-ms-presented-at-aan-2025/2474004/Results from an open-label extension (OLE) of a phase 2 clinical trial (NCT04879628) for frexalimab (Sanofi; Bridgewater, NJ), an investigational CD40 ligand inhibitor not associated with lymphocyte depletion being studied as a potential treatment for people with relapsing multiple sclerosis, wer
- Switching to SC Kesimpta from IVAnti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/Switching-SC-Kesimpta-IVAnti-CD20-Therapies-Safe-Effective-Across-Diverse-Individuals-Relapsing-MS/2471739/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Switching to SC Kesimpta from IV Anti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/kesimpta-maintains-efficacy-across-race-and-ethnic-groups-in-relapsing-ms-patients-transitioning-from-intravenous-anti-cd20-therapies/2473797/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Washout Period Following Dimethyl Fumarate Treatment Cessation Associated with MS Disease Activity and Relapsehttps://practicalneurology.com/news/washout-period-duration-following-dimethyl-fumarate-treatment-cessation-associated-with-ms-disease-activity-and-relapse/2470484/According to results presented at the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), disease activity was significantly associated with the duration of the interval between cessation of dimethyl fumarate (DMF) treatment and the initiation of an alternative disease-mod
- One-Year Data from OCARINA II Show Suppression of Relapses/Lesions in MS with Subcutaneous Ocrevus Treatmenthttps://practicalneurology.com/news/one-year-data-from-ocarina-ii-show-suppression-of-relapseslesions-in-ms-with-subcutaneous-ocrevus-treatment/2470456/Data from the OCARINA II study (NCT05232825) presented at the American Academy of Neurology (AAN) 2024 Annual Meeting showed that subcutaneous (SC) injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in near-complete suppression of clinical relapses and brain lesions i
- Prognostic Value of Serum NfL for Predicting Lesion Formation in MS Affirmed by ASCLEPIOS I/IIhttps://practicalneurology.com/news/prognostic-value-of-serum-nfl-for-predicting-lesion-formation-in-ms-affirmed-by-asclepios-iii/2470447/People with relapsing multiple sclerosis (RMS) who had higher 3- and 12-month on-treatment serum neurofilament light chain (sNfL) levels were found to have higher annualized rates of new or emerging T2 (neT2) lesion formation, according to findings from the phase 3 ASCLEPIOS I/II clinical trials
- Investigational Small Molecule Therapy for Progressive MS Associated with Reduced Serum NfL Levels Compared with Placebohttps://practicalneurology.com/news/vidofludimus-calcium-reduces-serum-nfl-levels-compared-with-placebo-in-those-with-progressive-ms/2470416/According to interim analysis of the CALLIPER clinical trial (NCT05054140), people with progressive multiple sclerosis (PMS) subtypes who were treated with VidoCa (vidofludimus calcium; Immunic, New York, NY) as an oral tablet for 24 weeks showed a significant reduction in serum neurofilament lig
- Data from Danish MS Registry Study Provide Patterns and Predictors for Conversion from RRMS to SPMShttps://practicalneurology.com/news/data-from-danish-ms-registry-study-provide-patterns-and-predictors-for-conversion-from-rrms-to-spms/2470309/Researchers analyzing data from the Danish Multiple Sclerosis Registry revealed patterns and predictors for conversion from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SMPS). In all, 21.8% of people with relapsing-remitting multiple sclerosis (RRMS)